Budget impact analysis of adjunctive therapy with lacosamide for partial-onset epileptic seizures in Belgium

Journal of Medical Economics

Volumn 14, Issue 3, 2011, Pages 299-304

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Belgium; Budget impact; lacosamide; Partialonset seizures; Refractory epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; TOPIRAMATE; VALPROIC ACID;

ADJUVANT THERAPY; ARTICLE; BELGIUM; BUDGET; BUDGET IMPACT ANALYSIS; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG TREATMENT FAILURE; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; METHODOLOGY; SEIZURE; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ACETAMIDES; ADOLESCENT; ANTICONVULSANTS; BELGIUM; BUDGETS; DRUG COSTS; EPILEPSY, PARTIAL, SENSORY; HUMANS;

EID: 79956116939     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.577852     Document Type: Article

References (23)

1. Hauser W. Epilepsy: Frequency, Causes, and Consequences. New York: Demos Press, 1990
2. Kotsopoulos IA, van Merode T, Kessels FG, et al. Systematic review and metaanalysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 2002;43:1402-9 (Pubitemid 35365000)
3. Hitiris N, Mohanraj R, Norrie J, et al. Mortality in epilepsy. Epilepsy Behav 2007;10:363-76 (Pubitemid 46577939)
4. Pugliatti M, Beghi E, Forsgren L, et al. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007;48:2224-33 (Pubitemid 350243405)
5. Brodie MJ. Epilepsy: randomised trials and genetic tribulations. Lancet Neurol 2008;7:7-8 (Pubitemid 350251922)
6. Leppik I, Morrell M, Godfroid P, et al. Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy. Epilepsia 2003;44:1350-52 (Pubitemid 37280380)
7. Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005;9:1-157, iii-iv
8. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308-17 (Pubitemid 47063096)
9. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010;51:958-67
10. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Lacosamide: efficacy and safety as oral adjunctive therapy in adults with partial seizures. Epilepsia 2006;47(Suppl 4):3
11. Cohen J, Stolk E, Niezen M. The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics 2007;25:727-34 (Pubitemid 47481638)
12. Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoecon Outcomes Res 2005;5:65-79 (Pubitemid 40590125)
13. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices - budget impact analysis. Value Health 2007;10:336-47 (Pubitemid 47481105)
14. National Statistics of Belgium. Available at: http://www.statbel.fgov.be/ [Last accessed 6 September 2010]
15. Boon P, De Deyn PP, Hauman H, et al. Epidemiologie van epileptische toevallen in Vlaanderen. Tijdschr Geneeskund 1996;52:47
16. Hauser WA. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993;34:453-68 (Pubitemid 23184580)
17. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008;70:54-65
18. National Institute for Health and Clinical Excellence. Newer drugs for epilepsy in adults. London: National Institute for Health and Clinical Excellence, 2004
19. Scottish Medicines Consortium. Lacosamide. Edinburgh: Scottish Medicines Consortium, 2009
20. Cleemput I, Van Wilder P, Vrijens F, et al. Richtlijnen voor farmacoeconomische evaluaties in België. Brussel: Federaal Kenniscentrum voor de Gezondheidszorg, 2008
21. Simoens S, Dedeken P, Benhaddi H. Cost-utility analysis of lacosamide adjunctive therapy in the treatment of partial-onset seizures in epileptic patients in Belgium. Presentation at the ISPOR 13th Annual European Congress. Prague, Czech Republic, 6-9th November 2010
22. Soini E, Martikainen J, Vanoli A. Cost-effectiveness and budget impact modeling of lacosamide in the treatment of partial-onset seizures in Finland. Value Health 2009;12:A367
23. Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures - cost utility results for Sweden. Acta Neurol Scand 2010;121:406-12